Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation

Cardiovascular Research

Volumn 113, Issue 7, 2017, Pages 737-748

  Mansor, Latt S ^a   Sousa Fialho, Maria da Luz ^a   Yea, Georgina ^a   Coumans, Will A ^b   West, James A ^c   Kerr, Matthew ^a   Carr, Carolyn A ^a   Luiken, Joost J F P ^b   Glatz, Jan F C ^b   Evans, Rhys D ^a   Griffin, Julian L ^c   Tyler, Damian J ^a   Clarke, Kieran ^a   Heather, Lisa C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Energy; Fatty acid; Glucose; Hypoxia; Metabolism

Indexed keywords

ACETYL COENZYME A; ADENINE; ADENOSINE TRIPHOSPHATE; ALANINE; ASPARAGINE; ASPARTIC ACID; CD36 ANTIGEN; CREATINE PHOSPHATE; FATTY ACID; FUMARIC ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE DISULFIDE; HISTIDINE; INSULIN; ISOLEUCINE; LACTIC ACID; LEUCINE; LYSINE; MALIC ACID; OLEIC ACID; OXALOACETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHENYLALANINE; PYRUVATE DEHYDROGENASE; SUCCINIC ACID; SULFO N SUCCINIMIDYL OLEATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CD36 PROTEIN, RAT; SUCCINIMIDE DERIVATIVE; SULFO-N-SUCCINIMIDYL OLEATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; ENZYME ACTIVITY; EXPERIMENTAL HYPOXIA; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART PERFUSION; IN VIVO STUDY; INSULIN BLOOD LEVEL; ISOLATED HEART; LIPID STORAGE; MALE; METABOLIC RATE; METABOLOMICS; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; REOXYGENATION; SARCOLEMMA; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CELL HYPOXIA; COMPLICATION; DIABETIC CARDIOMYOPATHY; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE PRESSURE; LIPID METABOLISM; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; TIME FACTOR; WISTAR RAT;

ANIMALS; CD36 ANTIGENS; CELL HYPOXIA; CITRIC ACID CYCLE; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; ENERGY METABOLISM; FATTY ACIDS; ISOLATED HEART PREPARATION; LIPID METABOLISM; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OLEIC ACIDS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS, WISTAR; SARCOLEMMA; SUCCINIMIDES; TIME FACTORS; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 85026795583     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvx045     Document Type: Article

References (52)

1. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 2009;54:1524–1532.
2. Jagasia D, Whiting JM, Concato J, Pfau S, McNulty PH. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 2001;103:1734–1739.
3. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004;109:2191–2196.
4. Hafstad AD, Solevag GH, Severson DL, Larsen TS, Aasum E. Perfused hearts from Type 2 diabetic (db/db) mice show metabolic responsiveness to insulin. Am J Physiol Heart Circ Physiol 2006;290:H1763–H1769.
5. Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004;53:2366–2374.
6. Boardman N, Hafstad AD, Larsen TS, Severson DL, Aasum E. Increased O2 cost of basal metabolism and excitation-contraction coupling in hearts from type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2009;296:H1373–H1379.
7. Mansor LS, Mehta K, Aksentijevic D, Carr CA, Lund T, Cole MA, Page LL, Sousa Fialho Mda L, Shattock MJ, Aasum E, Clarke K, Tyler DJ, Heather LC. Increased oxidative metabolism following hypoxia in the type 2 diabetic heart, despite normal hypoxia signalling and metabolic adaptation. J Physiol 2016;594:307–320.
8. Luiken JJ, Arumugam Y, Bell RC, Calles-Escandon J, Tandon NN, Glatz JF, Bonen A. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol Endocrinol Metab 2002;283:E612–E621.
9. Carley AN, Atkinson LL, Bonen A, Harper ME, Kunnathu S, Lopaschuk GD, Severson DL. Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch Physiol Biochem 2007;113:65–75.
10. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785–789.
11. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000;99:27–35.
12. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280–3288.
13. Abozguia K, Clarke K, Lee L, Frenneaux M. Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med 2006;3:490–498.
14. Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones PG, Olmsted A, Belardinelli L, Chaitman BR. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol 2013;61:2038–2045.
15. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003;146:E18.
16. Schmitz FJ, Rosen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir. Horm Metab Res 1995;27:515–522.
17. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007;100:1208–1217.
18. Oakes ND, Thalen P, Aasum E, Edgley A, Larsen T, Furler SM, Ljung B, Severson D. Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes. Am J Physiol Endocrinol Metab 2006;290:E870–E881.
19. Mather KJ, Hutchins GD, Perry K, Territo W, Chisholm R, Acton A, Glick-Wilson B, Considine RV, Moberly S, DeGrado TR. Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer. Am J Physiol Endocrinol Metab 2016;310:E452–E460.
20. Essop MF, Anna Chan WY, Valle A, Garcia-Palmer FJ, Du Toit EF. Impaired contractile function and mitochondrial respiratory capacity in response to oxygen deprivation in a rat model of pre-diabetes. Acta physiologica 2009;197:289–296.
21. Mokuda O, Sakamoto Y, Ikeda T, Mashiba H. Effects of anoxia and low free fatty acid on myocardial energy metabolism in streptozotocin-diabetic rats. Ann Nutr Metab 1990;34:259–265.
22. Beauloye C, Bertrand L, Krause U, Marsin AS, Dresselaers T, Vanstapel F, Vanoverschelde JL, Hue L. No-flow ischemia inhibits insulin signaling in heart by decreasing intracellular pH. Circ Res 2001;88:513–519.
23. West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax 2006;61:945–950.
24. Klein OL, Krishnan JA, Glick S, Smith LJ. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabet Med 2010;27:977–987.
25. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105–113.
26. Le Page LM, Rider OJ, Lewis AJ, Ball V, Clarke K, Johansson E, Carr CA, Heather LC, Tyler DJ. Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study. Diabetes 2015;64:2735–2743.
27. Mansor LS, Gonzalez ER, Cole MA, Tyler DJ, Beeson JH, Clarke K, Carr CA, Heather LC. Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin. Cardiovasc Diabetol 2013;12:136–145.
28. Watts LM, Manchem VP, Leedom TA, Rivard AL, McKay RA, Bao D, Neroladakis T, Monia BP, Bodenmiller DM, Cao JX, Zhang HY, Cox AL, Jacobs SJ, Michael MD, Sloop KW, Bhanot S. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 2005;54:1846–1853.
29. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2009;2:454–66.
30. Staros JV. N-hydroxysulfosuccinimide active esters: bis(N-hydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry 1982;21:3950–3955.
31. Lopaschuk GD, Barr RL. Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol Cell Biochem 1997;172:137–147.
32. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497–509.
33. Seymour AM, Chatham JC. The effects of hypertrophy and diabetes on cardiac pyruvate dehydrogenase activity. J Mol Cell Cardiol 1997;29:2771–2778.
34. Le Belle JE, Harris NG, Williams SR, Bhakoo KK. A comparison of cell and tissue extraction techniques using high-resolution 1H-NMR spectroscopy. NMR Biomed 2002;15:37–44.
35. Heather LC, Cole MA, Lygate CA, Evans RD, Stuckey DJ, Murray AJ, Neubauer S, Clarke K. Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. Cardiovasc Res 2006;72:430–437.
36. Luiken JJ, Koonen DP, Willems J, Zorzano A, Becker C, Fischer Y, Tandon NN, Van Der Vusse GJ, Bonen A, Glatz JF. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 2002;51:3113–3119.
37. Heather LC, Cole MA, Atherton HJ, Coumans WA, Evans RD, Tyler DJ, Glatz JF, Luiken JJ, Clarke K. Adenosine monophosphate-activated protein kinase activation, substrate transporter translocation, and metabolism in the contracting hyperthyroid rat heart. Endocrinology 2010;151:422–431.
38. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121–130.
39. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 2003;100:1226–1231.
40. Harmon CM, Luce P, Beth AH, Abumrad NA. Labeling of adipocyte membranes by sulfo-N-succinimidyl derivatives of long-chain fatty acids: inhibition of fatty acid transport. J Membr Biol 1991;121:261–268.
41. Harmon CM, Abumrad NA. Binding of sulfosuccinimidyl fatty acids to adipocyte membrane proteins: isolation and amino-terminal sequence of an 88-kD protein implicated in transport of long-chain fatty acids. J Membr Biol 1993;133:43–49.
42. Abumrad NA, el-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 1993;268:17665–17668.
43. Luiken JJ, van Nieuwenhoven FA, America G, van der Vusse GJ, Glatz JF. Uptake and metabolism of palmitate by isolated cardiac myocytes from adult rats: involvement of sarcolemmal proteins. J Lipid Res 1997;38:745–758.
44. Coort SL, Willems J, Coumans WA, van der Vusse GJ, Bonen A, Glatz JF, Luiken JJ. Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem 2002;239:213–219.
45. Angin Y, Steinbusch LK, Simons PJ, Greulich S, Hoebers NT, Douma K, van Zandvoort MA, Coumans WA, Wijnen W, Diamant M, Ouwens DM, Glatz JF, Luiken JJ. CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochem J 2012;448:43–53.
46. Sohn K, Wende AR, Abel ED, Moreno AP, Sachse FB, Punske BB. Absence of glucose transporter 4 diminishes electrical activity of mouse hearts during hypoxia. Exp Physiol 2013;98:746–757.
47. Aomine M, Nobe S, Arita M. Increased susceptibility to hypoxia of prolonged action potential duration in ventricular papillary muscles from diabetic rats. Diabetes 1990;39:1485–1489.
48. Montessuit C, Lerch R. Regulation and dysregulation of glucose transport in cardiomyocytes. Biochim Biophys Acta 2013;1833:848–856.
49. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, Logan A, Nadtochiy SM, Ord EN, Smith AC, Eyassu F, Shirley R, Hu CH, Dare AJ, James AM, Rogatti S, Hartley RC, Eaton S, Costa AS, Brookes PS, Davidson SM, Duchen MR, Saeb-Parsy K, Shattock MJ, Robinson AJ, Work LM, Frezza C, Krieg T, Murphy MP. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014;515:431–435.
50. Banke NH, Lewandowski ED. Impaired cytosolic NADH shuttling and elevated UCP3 contribute to inefficient citric acid cycle flux support of postischemic cardiac work in diabetic hearts. J Mol Cell Cardiol 2015;79:13–20.
51. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;277:50230–50236.
52. Sparagna GC, Hickson-Bick DL, Buja LM, McMillin JB. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 2000;279:H2124–H2132.